摘要
Hepatocellular carcinoma(HCC)remains the third most common cause of cancer-related deaths worldwide(1).Transarterial chemoembolization(TACE)has been established as a therapeutic option in those patients who are outside of surgical resection or transplant criteria for over four decades(2).Multiple expert panels have outlined the appropriate use criteria and recommendations for HCC treatment(3-5).These documents have focused on multiple treatment modalities including interventional radiology intra-arterial and ablative treatments as well as resection,transplant and systemic therapy.In their recently published practice recommendations for the use of TACE in HCC patients,the Korean Liver Cancer Association(KLCA)has developed a comprehensive list of recommendations for this specific modality(6).The recommendations are a combination of evidence-based,expert consensus decisions and surveys of Korean experts in TACE for HCC.Comparing and contrasting this focused guideline on TACE to the recent HCC guidelines from the National Comprehensive Cancer Network(NCCN),American Association for the Study of Liver Diseases(AASLD)and Barcelona Clinic Liver Cancer(BCLC)is valuable to understand where methods are truly global and also to understand differences in treatment approach by region.
